# PROGENICS PHARMACEUTICALS INC

PROGENICS PHARMACEUTICALS INC is a company headquartered in New York, NY, United States.

## Company overview

- **Legal name:** PROGENICS PHARMACEUTICALS INC
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** New York, NY, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0000835887

## About

PROGENICS PHARMACEUTICALS INC is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0000835887, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2020-03-13, it reported annual revenue of USD 34,986,000; net income of USD -68,552,000; total assets of USD 119,470,000 for the fiscal period ended 2019-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2019 (period ended 2019-12-31)

- **Revenue:** $35.0M (USD 34,986,000)
- **Net income:** -$68.6M (USD -68,552,000)
- **Total assets:** $119.5M (USD 119,470,000)
- **Cash and equivalents:** $42.0M (USD 42,049,000)
- **Operating cash flow:** -$74.7M (USD -74,698,000)

### FY2018 (period ended 2018-12-31)

- **Revenue:** $15.6M (USD 15,622,000)
- **Net income:** -$67.7M (USD -67,657,000)
- **Total assets:** $169.5M (USD 169,497,000)
- **Cash and equivalents:** $137.7M (USD 137,686,000)
- **Operating cash flow:** -$46.8M (USD -46,752,000)

### FY2017 (period ended 2017-12-31)

- **Revenue:** $11.7M (USD 11,698,000)
- **Net income:** -$51.0M (USD -51,013,000)
- **Total assets:** $146.0M (USD 145,957,000)
- **Cash and equivalents:** $90.6M (USD 90,642,000)
- **Operating cash flow:** -$53.6M (USD -53,628,000)
- **Later filings:** Operating cash flow: shown as originally filed; later filings report different values for the same periods.

### FY2016 (period ended 2016-12-31)

- **Revenue:** $69.4M (USD 69,429,000)
- **Net income:** $10.8M (USD 10,806,000)
- **Total assets:** $199.0M (USD 198,986,000)
- **Cash and equivalents:** $138.9M (USD 138,909,000)

## Recent SEC filings

- Form 8-K — filed 2020-06-22 — period 2020-06-19 — 8-K
- Form 8-K — filed 2020-06-17 — period 2020-06-16 — 8-K
- Form 8-K — filed 2020-06-16 — period 2020-06-16 — 8-K
- Form 8-K — filed 2020-06-11 — period 2020-06-05 — FORM 8-K
- Form 8-K — filed 2020-06-08 — period 2020-06-08 — 8-K
- Form 8-K — filed 2020-05-28 — period 2020-05-22 — FORM 8-K
- Form 8-K — filed 2020-05-18 — period 2020-05-18 — FORM 8-K
- Form 10-Q — filed 2020-05-07 — period 2020-03-31 — FORM 10-Q
- Form 8-K — filed 2020-05-07 — period 2020-05-07 — FORM 8-K
- Form SC 13D — filed 2020-04-23 — SC 13D
- Form 8-K — filed 2020-04-14 — period 2020-04-14 — 8-K
- Form 8-K — filed 2020-04-02 — period 2020-04-02 — 8-K

---

Updated: 2026-10-23T20:12:17Z

Canonical page: https://altss.com/profile/progenics-pharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology